Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine

Sajjad Desai, Niraj Rathi, Anand Kawade, Padmasani Venkatramanan, Ritabrata Kundu, Sanjay K Lalwani, A P Dubey, J Venkateswara Rao, D Narayanappa, Radha Ghildiyal, Nithya J Gogtay, P Venugopal, Sonali Palkar, Renuka Munshi, Ashish Bavdekar, Sanjay Juvekar, Nupur Ganguly, Prabal Niyogi, Kheya Ghosh Uttam, Alpana Kondekar, Dipti Kumbhar, Smilu Mohanlal, Mukesh C Agarwal, Parvan Shetty, Kalpana Antony, Bhagwat Gunale, Abhijeet Dharmadhikari, Jagdish Deshpande, Uma Nalavade, Deepa Sharma, Anurag Bansal, Yuxiao Tang, Jorge Flores, Prasad S Kulkarni, Sajjad Desai, Niraj Rathi, Anand Kawade, Padmasani Venkatramanan, Ritabrata Kundu, Sanjay K Lalwani, A P Dubey, J Venkateswara Rao, D Narayanappa, Radha Ghildiyal, Nithya J Gogtay, P Venugopal, Sonali Palkar, Renuka Munshi, Ashish Bavdekar, Sanjay Juvekar, Nupur Ganguly, Prabal Niyogi, Kheya Ghosh Uttam, Alpana Kondekar, Dipti Kumbhar, Smilu Mohanlal, Mukesh C Agarwal, Parvan Shetty, Kalpana Antony, Bhagwat Gunale, Abhijeet Dharmadhikari, Jagdish Deshpande, Uma Nalavade, Deepa Sharma, Anurag Bansal, Yuxiao Tang, Jorge Flores, Prasad S Kulkarni

Abstract

Background: A newly developed bovine-human reassortant pentavalent vaccine (BRV-PV, ROTASIIL®) was tested for its potential effect on the immunogenicity of concomitantly administered EPI vaccines in infants in a randomized controlled study in India.

Methods: In this Phase III, multicenter, open label, randomized, controlled study, three doses of BRV-PV or two doses of Rotarix® and one dose of placebo were given to healthy infants at 6, 10, and 14 weeks of age. Subjects also received three doses of DTwP-HepB-Hib (diphtheria, tetanus, whole-cell pertussis, hepatitis B, and haemophilus influenzae type b conjugate - pentavalent vaccine) and oral polio vaccine concomitantly at 6, 10, and 14 weeks of age and a single dose of inactivated polio vaccine at 14 weeks of age. Blood samples were collected four weeks after the final vaccination to assess immune responses to all the vaccines administered. For diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 antibodies, non-interference was to be supported if the lower limit of the two-sided 90% confidence interval (CI) for the seroprotection rate difference for the BRV-PV group minus the Rotarix® group was >10.0%. For pertussis antibodies, non-interference was to be supported if the lower limit of the two-sided 90% CI for the ratio of geometric mean concentrations (GMCs) was >0.5.

Results: A total of 1500 infants were randomized to either BRV-PV (1125 infants) or Rotarix® (375 infants), of which 1341 completed the study as per the protocol. More than 97% of subjects achieved seroprotective antibody titres against diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 in both groups. The difference in seroprotection rates between the BRV-PV group and the Rotarix® group for all these antibodies was less than 1%. The ratio of GMCs of anti-pertussis IgG concentrations for the BRV-PV group versus Rotarix® was 1.04 [90% CI: 0.90; 1.19].

Conclusion: BRV-PV does not interfere with the immunogenicity of concomitantly administered routine infants vaccines.

Trial registration: ClinicalTrials.gov NCT02584816.

Keywords: Bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV); DTwP-HepB-Hib vaccine; Immune response; Interference; Oral polio vaccine (OPV).

Copyright © 2018. Published by Elsevier Ltd.

References

    1. Tate J.E., Burton A.H., Boschi-Pinto C., Parashar U.D. World Health Organization-coordinated global rotavirus surveillance network. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016;62(Suppl 2):S96–S105.
    1. Rotavirus vaccines. WHO position paper – January 2013.Wkly Epidemiol Rec 2013 February 1; 88(5): p. 49–64.
    1. Immunization coverage. Fact sheet. Updated July 2017. [accessed 13.09.17].
    1. Zade J.K., Kulkarni P.S., Desai S.A., Sabale R.N., Naik S.P., Dhere R.M. Bovine rotavirus pentavalent vaccine development in India. Vaccine. 2014;32(Suppl 1):A124–A128.
    1. Naik S.P., Zade J.K., Sabale R.N., Pisal S.S., Menon R., Bankar S.G. Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®) Vaccine. 2017;35(22):2962–2969.
    1. Isanaka S., Guindo O., Langendorf C., MatarSeck A., Plikaytis B.D., Sayinzoga-Makombe N. Efficacy of a low-cost, heat-stable oral rotavirus vaccine in niger. N Engl J Med. 2017;376(12):1121–1130.
    1. Kulkarni P.S., Desai S., Tewari T., Kawade A., Goyal N., Garg B.S., Kumar D. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35(45):6228–6237.
    1. Clinical considerations for evaluation of vaccines for prequalification. Points to consider for manufacturers of human vaccines. October 2010. [accessed 13.09.17].
    1. Steele A.D., De Vos B., Tumbo J. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine. 2010;28(39):6542–6548.
    1. Vesikari T., Karvonen A., Prymula R. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine. 2010;28(32):5272–5279.
    1. Dennehy P.H., Bertrand H.R., Silas P.E., Damaso S., Friedland L.R., Abu-Elyazeed R. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics. 2008;122(5):e1062–e1066.
    1. Goveia M.G., Ciarlet M., Owen K.E., Ranucci C.S. Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine. Ann N Y Acad Sci. 2011;1222:14–18.
    1. Patel M., Steele A.D., Parashar U.D. Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine. 2012;30(Suppl 1):A30–A35.
    1. Ing D.J., Glass R.I., Woods P.A., Simonetti M., Pallansch M.A., Wilcox W.D. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine. Am J Dis Child. 1991 Aug;145(8):892–897.
    1. Emperador D.M., Velasquez D.E., Estivariz C.F., Lopman B., Jiang B., Parashar U. Interference of monovalent, bivalent, and trivalent oral poliovirus vaccines on monovalent rotavirus vaccine immunogenicity in rural Bangladesh. Clin Infect Dis. 2016;62(2):150–156.
    1. Rennels M.B., Ward R.L., Mack M.E., Zito E.T. Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group. J Infect Dis. 1996;173(2):306–313.
    1. Zaman K., Fleming J.A., Victor J.C., Yunus M., Bari T.I., Azim T.I. Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in antirotavirus immunity: a randomized trial. J Infect Dis. 2016;213(11):1686–1693.
    1. [accessed 04.04.18].
    1. [accessed 04.04.18].
    1. Chandola T.R., Taneja S., Goyal N. ROTAVAC® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial. Heliyon. 2017;3(5)
    1. Sutter R.W., John T.J., Jain H., Agarkhedkar S. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010;376(9753):1682–1688.
    1. [accessed 20.07.18].
    1. [accessed 11.06.18].

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する